Sporadic and Familial Medullary Thyroid Carcinoma: State of the Art

Surgical Clinics of North America

Volumn 89, Issue 5, 2009, Pages 1193-1204

  Moo Young, Tricia A ^a   Traugott, Amber L ^a   Moley, Jeffrey F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Medullary thyroid cancer; Multiple endocrine neoplasia; Preventative surgery; RET tyrosine kinase; Sporadic

Indexed keywords

LABETUZUMAB; SORAFENIB; SUNITINIB; TANESPIMYCIN; VANDETANIB;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; EXTERNAL BEAM RADIOTHERAPY; FAMILIAL CANCER; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; NEUROFIBROMATOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; REVIEW; RISK FACTOR; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

CARCINOMA, MEDULLARY; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2B; PHENOTYPE; PROGNOSIS; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349873816     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.06.021     Document Type: Review

References (36)

1. Khurana R., Agarwal A., Bajpai V.K., et al. Unraveling the amyloid associated with human medullary thyroid carcinoma. Endocrinology 145 12 (2004) 5465-5470 [Epub 2004 Sep 30]
2. Hazard J.B. The C cells (parafollicular cells) of the thyroid gland and medullary thyroid carcinoma. A review. Acta Neurol (Napoli) 32 4 (1977) 491-519
3. LiVolsi V.A. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82 1 (1997) 39-41
4. Howe J.R., Norton J.A., and Wells S.J. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 114 6 (1993) 1070-1077
5. Moers A.M., Landsvater R.M., Schaap C., et al. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101 6 (1996) 635-641
6. Farndon J.R., Leight G.S., Dilley W.G., et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 (1986) 278-281
7. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 19 (1996) 1575-1579
8. Chang T.C., Wu S.L., and Hsiao Y.L. Medullary thyroid carcinoma: pitfalls in diagnosis by fine needle aspiration cytology and relationship of cytomorphology to RET proto-oncogene mutations. Acta Cytol 49 5 (2005) 477-482
9. Mayr B., Brabant G., and von zur Muhlen A. Incidental detection of familial medullary thyroid carcinoma by calcitonin screening for nodular thyroid disease. Eur J Endocrinol 141 3 (1999) 286-289
10. Moley J.F., and DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229 6 (1999) 880-887 [discussion: 7-8]
11. Giraudet A.L., Vanel D., Leboulleux S., et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92 11 (2007) 4185-4190
12. Oudoux A., Salaun P.Y., Bournaud C., et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 92 12 (2007) 4590-4597
13. Machens A., Schneyer U., Holzhausen H.J., et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90 4 (2005) 2029-2034 [Epub 05 Jan 5]
14. Rendl L.M., Manzl M., Hitzl W., et al. Long-term prognosis of medullary thyroid carcinoma. Clin Endocrinol (Oxf) 69 3 (2008) 497-505
15. Machens A., Niccoli-Sire P., Hoegel J., et al. Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349 16 (2003) 1517-1525
16. Machens A., Hauptmann S., and Dralle H. Prediction of lateral lymph node metastases in medullary thyroid cancer. Br J Surg 95 5 (2008) 586-591
17. Moley J.F., and Fialkowski E.A. Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31 5 (2007) 946-956
18. Miyauchi A., Matsuzuka F., Hirai K., et al. Prospective trial of unilateral surgery for nonhereditary medullary thyroid carcinoma in patients without germline RET mutations. World J Surg 26 8 (2002) 1023-1028 [Epub 2002 May 21]
19. Fialkowski E., DeBenedetti M., and Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. World J Surg 32 5 (2008) 754-765
20. Moley J.F., Lairmore T.C., Doherty G.M., et al. Preservation of the recurrent laryngeal nerves in thyroid and parathyroid reoperations. Surgery 126 4 (1999) 673-677 [discussion: 7-9]
21. Brierley J., Tsang R., Simpson W.J., et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6 4 (1996) 305-310
22. Stein R., and Goldenberg D.M. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy. Mol Cancer Ther 3 12 (2004) 1559-1564
23. Cohen M.S., Hussain H.B., and Moley J.F. Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132 6 (2002) 960-966 [discussion: 6-7]
24. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 24 (2002) 7284-7290
25. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 5 (2006) 326-334
26. Chow L.Q., and Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25 7 (2007) 884-896
27. Hong D., Ye L., Gagel R., et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7 5 (2008) 1001-1006
28. Dottorini M.E., Assi A., Sironi M., et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 77 8 (1996) 1556-1565
29. Kebebew E., Ituarte P.H., Siperstein A.E., et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 5 (2000) 1139-1148
30. Quayle F.J., Fialkowski E.A., Benveniste R., et al. Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142 6 (2007) 800-805 [discussion: 805 e1]
31. Raue F., and Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 8 1 (2009) 23-28
32. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 12 (2001) 5658-5671
33. Skinner M.A., Moley J.A., Dilley W.G., et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353 11 (2005) 1105-1113
34. Eng C., Mulligan L.M., Smith D.P., et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12 3 (1995) 209-212
35. Zedenius J., Larsson C., Bergholm U., et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80 10 (1995) 3088-3090
36. Elisei R., Cosci B., Romei C., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93 3 (2008) 682-687